title: c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.
authors: Department of Haematology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK.
authors: Claire M
authors: CM
authors: Lucas
authors: Department of Haematology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK.
authors: Robert J
authors: RJ
authors: Harris
authors: Department of Haematology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK.
authors: Athina
authors: A
authors: Giannoudis
authors: Department of Haematology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK cml@liv.ac.uk.
authors: Richard E
authors: RE
authors: Clark
mesh_terms: D001324:Autoantigens / Q000378:metabolism*; D045744:Cell Line, Tumor; D004789:Enzyme Activation / Q000187:drug effects; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism*; D016271:Proto-Oncogene Proteins c-myc / Q000037:antagonists & inhibitors* / Q000235:genetics; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: C524814:5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; D001324:Autoantigens; C500266:CIP2A protein, human; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D016271:Proto-Oncogene Proteins c-myc; D034741:RNA, Small Interfering; D013844:Thiazoles; D016044:Fusion Proteins, bcr-abl
keywords: 10058-F4; CIP2A; CML; MYC; PP2A